What Happens When Meta Rejects Your Peptide Ads
We process Meta ad rejections for compounding pharmacies and peptide brands every week. The rejection notice lands in your Ads Manager and the instinct is to hit appeal immediately. Do not do that. An appeal filed without fixing the underlying trigger burns your chance at a human review and leaves a strike on your account history.
Meta's rejection system is automated. A classification model scans your ad copy, your landing page, your Business Manager history, and your domain reputation. If any of those signals trips a threshold, the ad gets rejected within minutes. The good news is that the triggers are consistent. Once you know what they are, you can remove them before submitting a single ad.
We have recovered banned peptide ad accounts that had been written off as permanently disabled. The pattern is always the same. Fix the compliance infrastructure first, then appeal with documentation. Skip the infrastructure step and the appeal fails, no matter how well written it is.
The Regulatory Framework Behind Every Rejection
FDA 503A governs traditional compounding pharmacies. Under 503A, compounded medications are prepared for individual patients based on a valid prescription. You cannot advertise 503A-compounded drugs as FDA-approved. You can advertise compounding services and mention that preparations occur under FDA-regulated conditions. The distinction between FDA-approved and FDA-regulated is the single most important compliance concept in peptide advertising.
FDA 503B covers outsourcing facilities that compound at scale. 503B facilities face the same advertising restrictions as 503A plus additional requirements around sterility documentation and batch records. Meta's reviewers look for evidence of 503B registration when evaluating ads that reference sterile compounding or batch production.
The Dietary Supplement Health and Education Act of 1994, Section 3, applies to peptides marketed as supplements. DSHEA prohibits any claim that a supplement treats, cures, or prevents disease. Structure-function claims are allowed but require the FDA disclaimer: 'This product is not intended to diagnose, treat, cure, or prevent any disease.' We include this disclaimer on every landing page that mentions peptides in a supplement context, even if the primary offering is a compounding service.
The BAV appeal pathway is your formal route to challenge a rejection. Business Asset Verification establishes that your business entity, domain, and regulatory registrations are legitimate. Verified businesses access a higher review tier with fewer automated rejections. We complete BAV verification for every client before running a single ad.
The Four Rejection Triggers We Fix Most Often
Trigger one: Specific peptide names in ad copy. BPC-157, semaglutide, tirzepatide, and similar terms trigger immediate automated rejection. Meta's keyword scanner flags them before a human ever sees the creative. We strip every peptide name from ad copy and move technical terminology to password-gated sections of the landing page.
Trigger two: Health outcome claims. Language suggesting weight loss, muscle growth, anti-aging, or treatment of a condition gets flagged. This includes implied claims like 'support your metabolic health' when paired with a product image. We rewrite every claim as a service description, not a product promise.
Trigger three: Landing page compliance gaps. Meta's crawler inspects your landing page with the same classification model used for ad review. Dosing guidance, before-and-after imagery, or patient testimonials referencing outcomes will get both the ad and the domain flagged. We audit landing pages before any campaign launch.
Trigger four: Unverified business documentation. If your pharmacy license, state registration, and domain ownership records are not on file through BAV verification, every ad faces elevated scrutiny. BAV is not optional for peptide advertisers. It is the foundation of a sustainable ad presence on Meta.
Pharmacy Reversal in 72 Hours
A compounding pharmacy client came to us with six rejected ad campaigns across two ad accounts. Their ads for semaglutide and tirzepatide compounding services were banned within hours of launch every time. The rejections cited Meta's Restricted Content policy with no further explanation.
We traced the problem to three specific issues. First, their landing page included a PDF download with dosing guidance and weight loss outcome language. Meta's crawler found the PDF and flagged the entire domain. Second, their Business Manager had no BAV verification on file. Third, their ad copy used 'semaglutide compounding' in the headline, which triggered the keyword scanner immediately.
We built a new landing page stripped of all dosing and outcome language. The page described compounding services and referenced FDA 503A compliance documentation. We removed every peptide name from ad copy and replaced clinical imagery with neutral pharmacy visuals. We completed BAV verification with the client's state pharmacy license and domain ownership documents.
The result was approval within 72 hours. The campaigns ran without rejection for nine consecutive months. The compliance infrastructure did the work. The ads simply reflected what the infrastructure already proved.
More reading
Compounding Pharmacy Ads Banned on Meta
Why Peptide Ads Get Banned
Ready to run these ads? Book a call → calendly.com/custodio-2/30min